Stocks Health care SXTC

NASDAQ · Health care

China SXT Pharmaceuticals, Inc. (SXTC)

China SXT Pharmaceuticals, Inc. reported revenue of $1.1M in fiscal 2026, down 34.6% from a year earlier. It posted a net loss of $6.2M. At March 31, 2026 it held $28.2M in cash against $644.4K of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on July 1, 2026.

Watch SXTC in 60 seconds

Follow SXTC

Free, no password. An email when SXTC files with the SEC.

Key facts about China SXT Pharmaceuticals, Inc.

Net worth

China SXT Pharmaceuticals, Inc. has a market value (market cap) of $1.4M at the latest share price, and shareholders' equity of $29.7M on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2026 revenue was $1.1M (-34.6% year on year), with a net loss of $6.2M.

Cash flow

In fiscal 2026 operations used $4M of cash.

Latest report

The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on July 1, 2026 and covers the period to March 31, 2026. Open on SEC EDGAR

What China SXT Pharmaceuticals, Inc. does

China SXT Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SXTC.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where SXTC ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What China SXT Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 28, 2026
   Form F-3/A filing F-3/A
2. August 28, 2026
   Foreign issuer update 6-K
3. July 24, 2026
   Foreign issuer update 6-K
4. July 7, 2026
   Form F-3 filing F-3
5. July 6, 2026
   Foreign issuer update 6-K
6. July 1, 2026
   Annual report (foreign issuer) 20-F · period to March 31, 2026Revenue fell 35% to $1.1M versus the prior year; diluted EPS -$9.13 versus -$348.17.
7. June 1, 2026
   Foreign issuer update 6-K
8. May 4, 2026
   Foreign issuer update 6-K
9. April 9, 2026
   Foreign issuer update 6-K
10. January 13, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 7, the latest on April 27, 2026. Insider transactions on SEC

Insider trades

What the people running China SXT Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns SXTC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Streeterville Capital LLC 0% (January 21, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about SXTC

What does China SXT Pharmaceuticals, Inc. do?

China SXT Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as SXTC. Its shares trade on NASDAQ under the ticker SXTC.

What is China SXT Pharmaceuticals, Inc.'s net worth?

China SXT Pharmaceuticals, Inc. has a market value (market cap) of $1.4M at the latest share price, and shareholders' equity of $29.7M on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is China SXT Pharmaceuticals, Inc. profitable?

No. In fiscal 2026 it reported a net loss of $6.2M on revenue of $1.1M.

How much revenue does China SXT Pharmaceuticals, Inc. make?

In fiscal 2026 China SXT Pharmaceuticals, Inc. reported revenue of $1.1M. That is 34.6% less than a year earlier.

When did China SXT Pharmaceuticals, Inc. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on July 1, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the form F-3/A filing from August 28, 2026.

Similar companies

Compare SXTC with

Compare SXTC with any company

Follow SXTC

Get an email when China SXT Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow SXTC

Free, no password. An email when SXTC files with the SEC.

Where the numbers come from

Financial figures are the values China SXT Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.